Search research articles
Contact Us
Filters
Showing results (361-370 of 401) with videos related to
Page
of 41
Sort By:
Plos Genetics
|
December 18, 2007
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis
Nigel P S Crawford, Xiaolan Qian, Argyrios Ziogas, et al.
Journal of the National Cancer Institute. Monographs
|
November 12, 2024
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial
Carolina Porras, Byron Romero, Troy Kemp, et al.
The Journal of Infectious Diseases
|
October 23, 1997
Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women
E I Svare, S K Kjaer, B Nonnenmacher, et al.
Journal of the National Cancer Institute
|
October 16, 2015
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection
Daniel C Beachler, Aimée R Kreimer, Mark Schiffman, et al.
Journal of the National Cancer Institute
|
April 11, 2023
Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial
Brian Befano, Nicole G Campos, Didem Egemen, et al.
Cancer Cell
|
June 14, 2022
Cancer vaccines
John T Schiller, Douglas R Lowy, Ian H Frazer, et al.
Cancer
|
November 14, 2025
The impact of focused federal initiatives on pediatric cancer research
Subhashini Jagu, Malcolm A Smith, Nita L Seibel, et al.
Journal of Biotechnology and Biomedicine
|
June 28, 2024
cProSite: A web based interactive platform for online proteomics, phosphoproteomics, and genomics data analysis
Dunrui Wang, Xiaolan Qian, Yi-Chieh Nancy Du, et al.
Plos One
|
July 23, 2013
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica
Rolando Herrero, Wim Quint, Allan Hildesheim, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
November 6, 2013
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, et al.
Page
of 41
Search research articles
Search
Showing results (361-370 of 401) with videos related to
Sort By:
Page
of 41
Plos Genetics
|
December 18, 2007
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis
Nigel P S Crawford, Xiaolan Qian, Argyrios Ziogas, et al.
Journal of the National Cancer Institute. Monographs
|
November 12, 2024
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial
Carolina Porras, Byron Romero, Troy Kemp, et al.
The Journal of Infectious Diseases
|
October 23, 1997
Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women
E I Svare, S K Kjaer, B Nonnenmacher, et al.
Journal of the National Cancer Institute
|
October 16, 2015
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection
Daniel C Beachler, Aimée R Kreimer, Mark Schiffman, et al.
Journal of the National Cancer Institute
|
April 11, 2023
Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial
Brian Befano, Nicole G Campos, Didem Egemen, et al.
Cancer Cell
|
June 14, 2022
Cancer vaccines
John T Schiller, Douglas R Lowy, Ian H Frazer, et al.
Cancer
|
November 14, 2025
The impact of focused federal initiatives on pediatric cancer research
Subhashini Jagu, Malcolm A Smith, Nita L Seibel, et al.
Journal of Biotechnology and Biomedicine
|
June 28, 2024
cProSite: A web based interactive platform for online proteomics, phosphoproteomics, and genomics data analysis
Dunrui Wang, Xiaolan Qian, Yi-Chieh Nancy Du, et al.
Plos One
|
July 23, 2013
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica
Rolando Herrero, Wim Quint, Allan Hildesheim, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
November 6, 2013
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, et al.
Page
of 41